Search articles in News

Found 1,531 articles

  • PharmiWeb.Jobs Welcomes Kintec Recruitment

    PharmiWeb.Jobs Welcomes Kintec Recruitment

    • 27 Jun 2022
    • Nola Cadman

    PharmiWeb.Jobs are delighted to welcome a new recruiter to our job board Kintec Recruitment!

  • PharmiWeb.Jobs Welcomes TFS Trial Form Support Int

    PharmiWeb.Jobs Welcomes TFS Trial Form Support International AB

    • 23 Jun 2022
    • Nola Cadman

    PharmiWeb.Jobs are delighted to welcome to the job board TFS Trial Form Support International AB

  • Kynos builds out senior management team with appoi

    Kynos builds out senior management team with appointment of Dr Alison Strutt, a seasoned biotech and ex-GSK executive, as CFO

    • 23 Jun 2022
    • Mike Wood

    Dr Alison Strutt joins Kynos senior management team as CFO Brings extensive strategic, transactional, and operational experience in biotech and large pharma to the Kynos leadership team

  • Transine Therapeutics poised for growth with new C

    Transine Therapeutics poised for growth with new CSO hire and tripling of lab space

    • 23 Jun 2022
    • Mike Wood

    Transine Therapeutics - Andy Billinton PhD appointed as Chief Scientific Officer Expansion into larger facilities at the Babraham Research Campus

  • Average UK Clinical Research Salaries in 2022

    Average UK Clinical Research Salaries in 2022

    • 22 Jun 2022
    • Lucy Walters

    With the UK’s Clinical Research industry booming, and with the current job market becoming increasingly candidate-driven, 2022 is an excellent time to be considering a career move within or into Clinical Research. Following on from our previous article outlining 10 Clinical Research career paths, we’ve used Indeed’s Salary Guide to put together this list of the average base salary in the UK for these 13 common Clinical Research roles.

  • Börje Haraldsson appointed CEO of Oncorena AB

    Börje Haraldsson appointed CEO of Oncorena AB

    • 21 Jun 2022
    • Editor

    Oncorena AB, which is developing a new and potentially groundbreaking treatment for patients with advanced kidney cancer, announces that the Board of Directors of Oncorena AB has appointed Professor Börje Haraldsson as CEO of the company, effective as of today. He thus succeeds Dr. Lars Grundemar, who will leave the company.

  • Verismo Therapeutics Announces Research Partnershi

    Verismo Therapeutics Announces Research Partnership with the University of Pennsylvania

    • 21 Jun 2022
    • Editor

    Verismo Therapeutics, a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T-cells, today announces that Penn and Verismo entered into a Sponsored Research Agreement (SRA). Under the SRA, Verismo is funding additional KIR-CAR T-cell focused preclinical research programs at Penn to advance new potential treatment options for solid tumor indications.

  • Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emer

    Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

    • 20 Jun 2022
    • Editor

    Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age (also referred to as 6 months to less than 5 years of age).

  • Moderna Receives FDA Authorization for Emergency U

    Moderna Receives FDA Authorization for Emergency Use of its COVID-19 Vaccine for Children 6 Months of Age and Older

    • 20 Jun 2022
    • Editor

    Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine (mRNA-1273) in young children ages 6 months through 5 years of age at a dose level of 25 µg. The company has also received emergency use authorization for a 50 μg two-dose regimen of mRNA-1273.

  • PharmiWeb.Jobs Welcomes Boehringer Ingelheim

    PharmiWeb.Jobs Welcomes Boehringer Ingelheim

    • 20 Jun 2022
    • Nola Cadman

    PharmiWeb.Jobs are delighted to welcome to the job board Boehringer Ingelheim.

  • Stephen Bardin to Join atai Life Sciences as CFO D

    Stephen Bardin to Join atai Life Sciences as CFO Designate

    • 17 Jun 2022
    • Editor

    atai Life Sciences N.V., (Nasdaq: ATAI) (“atai” or the “Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today that Stephen Bardin, currently Senior Vice President of Finance and Operations at BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio"), will be appointed Chief Financial Officer during the third quarter of 2022.

  • Weekly Life Science News Round Up: 13th – 17th Jun

    Weekly Life Science News Round Up: 13th – 17th June

    • 17 Jun 2022
    • Editor

    A round up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Devices sectors from 13th-17th June.

  • Parexel Expands Patient Access to Clinical Trials

    Parexel Expands Patient Access to Clinical Trials Through New Community Alliance Network

    • 17 Jun 2022
    • Editor

    Parexel, a leading global clinical research organization (CRO), today announced the launch of its Community Alliance Network, a novel program further integrating clinical research into the community healthcare setting to better serve patients and in turn create further opportunity for increased diversity in clinical trials. CVS Health®, the leading health care solutions company, and Javara, the leading Integrated Research Organization, have joined the network as inaugural members.

  • Banook group continues global expansion with US of

    Banook group continues global expansion with US office opening

    • 16 Jun 2022
    • Editor

    The Banook Group, specialized in cardiac safety, clinical imaging and endpoint adjudication, today announces the opening of its first US office in Boston, Massachusetts. This is the third international office for Banook since its inception in 1999, adding to its headquarters in Nancy (France), and locations in Munich (Germany) and Montreal (Canada).

  • Biocomposites appoints Group Chief Financial Offic

    Biocomposites appoints Group Chief Financial Officer and New UK General Manager

    • 15 Jun 2022
    • Editor

    Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce two new appointments.

  • Significant growth symbolic of biotech sector’s so

    Significant growth symbolic of biotech sector’s sovereign value

    • 15 Jun 2022
    • Editor

    The Australian Biotechnology Sector Snapshot (Snapshot) illuminates the sector’s 43 per cent growth since 2019 and 60 per cent growth since 2017; this research shows that 1,427 of the 2,654 organisations (54 per cent) are industry-based, with the number of companies undertaking biotech research and development having grown by 40% since 2019.

  • Boehringer Ingelheim signs Option to Acquire Truti

    Boehringer Ingelheim signs Option to Acquire Trutino Biosciences

    • 15 Jun 2022
    • Editor

    Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech company. Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases.

  • NorthX Biologics appoints industry veterans to its

    NorthX Biologics appoints industry veterans to its board of directors

    • 14 Jun 2022
    • Editor

    Sweden-based NorthX Biologics (“NorthX”), which focuses on process development and GMP manufacture of advanced biological drugs, has announced the appointments of Lotta Ljungqvist, Richard Bergström, Mathias Uhlén and Lars Backsell to its board of directors.

  • Anjarium Biosciences appoints Stephen Yoo, MD as C

    Anjarium Biosciences appoints Stephen Yoo, MD as Chief Executive Officer

    • 14 Jun 2022
    • Editor

    Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announced the appointment of Stephen Yoo, MD as the Company’s Chief Executive Officer (CEO).

  • Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally

    Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

    • 14 Jun 2022
    • Editor

    Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over.